Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has provided an announcement.
Lumos Diagnostics has secured Medicare reimbursement coverage for its FebriDx test from a fifth Medicare Administrative Contractor (MAC), WPS Health Solutions, retroactive from May 1, 2025. This achievement means Lumos now has coverage from five of the seven MACs, covering over 70% of US Medicare payments, which significantly enhances its access to the Medicare patient population. The company is actively negotiating with the remaining two MACs and aims to secure reimbursement from private insurers, striving for nationwide access and broad clinical adoption of FebriDx.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a leader in rapid, point-of-care diagnostic technologies. The company focuses on developing solutions that improve patient care, streamline the diagnostic and treatment process, and provide economic benefits to the healthcare system.
Average Trading Volume: 1,327,730
Technical Sentiment Signal: Sell
Current Market Cap: A$20.21M
For detailed information about LDX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue